|
|
叶定伟教授,复旦大学附属肿瘤医院泌尿肿瘤MDT首席专家,复旦大学前列腺肿瘤研究所所长、中国抗癌协会泌尿肿瘤专业委员会主任委员、中国临床肿瘤学会常务理事、中国临床肿瘤学会肾癌专家委员会副主任委员和免疫治疗专家委员会副主任委员、中国抗癌协会家族遗传性肿瘤协作组副主任委员、NCCN肾癌诊治指南中国版编写组副组长、NCCN前列腺癌和膀胱癌亚洲诊治共识专家委员会委员、上海市医师协会泌尿外科医师分会副会长、国科金终审专家、亚太前列腺癌学会(APPS)执行委员,亚太冷冻外科学会副会长。
主持国家级、省部级科研基金50余项。发表论文543篇(SCI 296篇)。主编主译专著9本,发明专利19项。牵头国际国内多中心临床实验和研究50余项。以第一完成人获上海市科技进步一等奖、教育部科技成果一等奖、上海市医学科技奖一等奖、中华医学奖二等奖,2012年获国家科技进步一等奖(第三完成人)。获国家卫计委有突出贡献中青年专家,吴阶平泌尿外科医学奖,上海市领军人才,上海市医学领军人才,上海市优秀学科带头人称号,全国卫生计生系统先进工作者称号,享受国务院特殊政府津贴。
研究领域:
擅长泌尿男性生殖系统肿瘤早期诊断、根治手术和综合治疗,尤其擅长前列腺癌、膀胱癌和肾癌的根治性手术。
研究团队:
泌尿外科现有医师22人,其中正高2人、副高6人、主治8人、住院6人、科研护士3人。在读研究生20人。
代表性论著:
-
Wei Y#, Wu J#, Gu W, Qin X, Dai B, Lin G, Gan H, Freedland SJ, Zhu Y*, Ye D*. Germline DNA Repair Gene Mutation Landscape in Chinese Prostate Cancer Patients. Eur Urol. 2019 Sep; 76(3):280-283.
-
2. Fu Q#, Xu L#, Wang Y#, Jiang Q#, Liu Z, Zhang J, Zhou Q, Zeng H, Tong S, Wang T, Qi Y, Hu B, Fu H, Xie H, Zhou L, Chang Y, Zhu Y, Dai B*, Zhang W*, Xu J*. Tumor-associated Macrophage derived Interleukin-23 Interlinks Kidney Cancer Glutamine Addiction with Immune Evasion. Eur Urol. 2019 May; 75(5):752-763
-
Fu H#, Zhu Y#, Wang Y#, Liu Z, Zhang J, Xie H, Fu, Q Dai B, Ye D*, Xu J*. Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer. Clinical Cancer Research. 2018; 24(13): 3069-3079.
-
Cao D#, Qi Z#, Pang Y#, Li H#, Xie H, Wu J, Huang Y, Zhu Y, Shen Y, Zhu Y, Dai B, Hu X, Ye D*, Wang Z*. Retinoic Acid–Related Orphan Receptor C Regulates Proliferation, Glycolysis, and Chemoresistance via the PD-L1ITGB6STAT3 Signaling Axis in Bladder Cancer. Cancer Res. 2019 May 15; 79(10):2604-2618.
-
Xu H#, Sun Y#, You BS, Huang CP, Ye DW*, Chawnshang Chang*. Androgen receptor reverses the oncometabolite R-2-hydroxyglutarate-induced prostate cancer cell invasion via suppressing the circRNA-51217/miRNA-646/TGFβ1/p-Smad2/3 signaling. Cancer Lett. 2020 Mar 1; 472:151-164.
-
Wang J#, Xu WH#, Wang BH, Lin GW, Wei Y, Mierxiati Abudurexiti , Zhu WK, Liu C, Qin XJ, Dai B, Wan FN*, Zhang HL*, Zhu Y*, Ye DW* . GLUT1 is an AR target contributing to tumor growth and glycolysis in castration-resistant and enzalutamide-resistant prostate cancersa. Cancer Lett. 2020 Aug 10; 485:45-55.
-
Zhu Y#, Liu, Z# Wang Y#, Fu H, Wang Z, Xie H , Zhang J, Li G, Dai B, Dingwei Ye*, Jiejie Xu*. High CXC chemokine receptor 1 level represents an independent negative prognosticator in non-metastatic clear-cell renal cell carcinoma patients. Oncoimmunology. 2017 Aug 8; 6(11):e1359450.
-
Xu WH#,Liu WR#,Xu Y#,Tian X#,A Anwaier,Su JQ,Zhu WK,Shi GH,Wei GM, Huang YP*, Qu YY*, Zhang HL*, Ye DW*. Hexokinase 3 dysfunction promotes tumorigenesis and immune escape by up-regulating monocyte/macrophage infiltration into clear cell renal cell carcinoma microenvironment. International Journal of Biological Sciences. 2021 Jun 1;17(9):2205-2222.
-
Wu J#, Wang H#, Ricketts CJ#, Yang Y, Merino MJ, Zhang H, Shi G, Gan H, Linehan WM*, Zhu Y*,Ye D*. Germline mutations of renal cancer predisposition genes and clinical relevance in Chinese sporadic early-onset patients. Cancer. 2019 Apr 1; 125(7):1060-1069.
-
Wang YC#, Wu J#, Luo WJ#, Zhang HL, Shi GH, Shen YJ, Zhu Y, Ma CG, Dai B, Ye DW*, Zhu YP*. ALPK2 acts as tumor promotor in development of bladder cancer through targeting DEPDC1A. Cell Death Dis. 2021 Jul 1; 12(7):661.
|